Emma Walmsley

Emma Walmsley
Born	Emma Natasha Walmsley Template:Birth year and age Barrow-in-Furness, Cumbria, England
Occupation(s)	Businesswoman, Chief Executive Officer
Years active	1990s–present
Known for	CEO of GSK plc

Dame Emma Natasha Walmsley DBE (born June 1969) serves as the chief executive officer (CEO) of GSK plc, having taken over from Sir Andrew Witty in April 2017. Before joining GSK, she dedicated 17 years to L'Oréal and held a non-executive director position at Diageo until September 2016. Walmsley grew up in Barrow-in-Furness, Cumbria, England.

Early life

Born in June 1969 in Barrow-in-Furness, Walmsley is the daughter of Vice-Admiral Sir Robert Walmsley and Lady Christina Walmsley (née Melvill). She completed her education at St Swithun's School, Winchester and obtained an MA in Classics and Modern Languages from Oxford University, where she studied at Christ Church.

Career

Walmsley’s 17-year tenure at L'Oréal included leadership roles in general management and marketing across Paris, London, and New York, notably as General Manager of Garnier-Maybelline. In 2007, she advanced to General Manager of Consumer Products for L'Oréal China based in Shanghai, managing brands such as L'Oréal Paris, Maybelline, Garnier, and the Chinese skincare line Mininurse. Her transition to GlaxoSmithKline in 2010 surprised some observers given her rising path toward senior global positions at L'Oréal.

Joining GlaxoSmithKline in May 2010 as President of Consumer Healthcare Europe, Walmsley was promoted in October 2011 to oversee the global consumer healthcare division as President of Consumer Healthcare Worldwide and became a member of the executive team. She was appointed CEO of Consumer Healthcare in March 2015, with a strategic emphasis on growing sales within emerging markets. Under her leadership, this segment—which includes brands like Panadol, Voltaren, and Horlicks—contributed nearly 25% of GSK’s overall revenue.

In April 2017, Walmsley made history as the first female CEO of a major pharmaceutical company when she assumed leadership of GSK. Market analysts interpreted her appointment as a commitment by GSK to retain its consumer health business as a central element. By August 2017, she emphasized strengthening GSK’s drug development and commercialization capabilities, focusing pharmaceutical R&D on four key disease areas that received 80% of capital investment. Nevertheless, industry commentators pointed out that GSK’s decision to maintain dividend payments constrained available resources for research and acquisitions.

She led substantial restructuring within R&D and by January 2018 had replaced fifty senior managers across various divisions of GSK. Additionally, she introduced new executive roles, including recruiting Karenann Terrell from Walmart as chief digital and technology officer.

Walmsley was honored with the title Dame Commander of the Order of the British Empire (DBE) in the 2020 Birthday Honours for her impact on pharmaceuticals and business leadership.

In 2023, her total remuneration reached $16 million—a 51% rise compared to 2022—ranking her as the second highest-paid CEO among European pharmaceutical firms.

Leadership style

A Financial Times profile published in 2016 characterizes Walmsley as a "strong and dynamic" leader who combines approachability with a resolute focus. She drives performance through clearly defined goals and stringent KPIs while balancing empathy and talent cultivation with firm action on underachievement.

Other roles

Walmsley holds a position on the board of GlaxoSmithKline. She was appointed as a non-executive director at Diageo from January until September 2016. In September 2019, she became an independent member of the Microsoft board.

Personal life

Walmsley practices yoga regularly. She wed David Owen in 1995 in Greenwich, London, and together they have four children.

Honours

In 2023, Walmsley was placed 7th on Fortune Magazine's list of the "100 Most Powerful Women" and ranked 15th on Forbes' "World's 100 Most Powerful Women." She previously secured the top spot on Fortune's 'Most Powerful International Women' ranking in 2018 and achieved second place in both 2017 and 2019.